239 Recruiting Trials

Clinical Trials
for Cancer in Nebraska

239 clinical trials for Cancer are currently recruiting participants at study sites in Nebraska. Study-related care is provided at no cost.

239
Recruiting trials
143
Study sites
11
Cities
152
Industry-sponsored
90
Phase 2
112
Phase 3

Cancer clinical trials in Nebraska: what to expect

Cancer is the single largest area of clinical research, and nearly every recruiting cancer trial is written for one cancer type at one stage. Most test a new drug or combination against the current standard treatment: targeted medicines matched to a mutation found in the tumor, immunotherapies that help the immune system recognize cancer cells, antibody-drug conjugates and cell therapies. Others study surgery and radiation techniques, ways to reduce side effects, and screening or prevention in people at higher risk.

In Nebraska, recruiting cancer studies are concentrated in Omaha, Lincoln, Grand Island and Kearney, with sites in 7 other cities. 152 of the 239 are run by a drug or device company, which usually means a larger study with travel reimbursement; the rest are academic or hospital-led.

Who cancer trials usually look for

Every listing names the cancer type and stage it enrolls, and most also state how many earlier treatments you may have had: some are for people newly diagnosed, many are for cancer that has come back or spread after a first treatment stopped working. Targeted-therapy trials require a specific result on tumor testing, which the site can arrange if it has not been done. Trials generally ask that you are well enough for daily activity (a "performance status" the doctor scores), that blood counts and liver and kidney function are adequate, and that a few weeks have passed since your last treatment.

Having advanced or metastatic cancer does not rule you out. A large share of recruiting trials are designed specifically for it.

What taking part involves

Screening reviews your pathology and scans, often with new blood work and sometimes a fresh biopsy. Treatment then follows a cycle, typically every two or three weeks, with scans every six to twelve weeks to measure the response. Early-phase trials have more frequent visits at the start. The study drug and study-specific tests are provided at no cost; standard care that you would receive anyway is usually billed to insurance as normal. A placebo on its own is rare in cancer trials: when there is one, it is added to the standard treatment, and the consent form says so.

Questions worth asking the study team

Whether the trial is randomized and what the comparison treatment is; what happens if the cancer grows during the study; whether you can keep receiving the drug afterward if it is working; how the trial fits with the plan your own oncologist has suggested; and what travel or lodging support is offered. Your oncologist can also refer you directly.

Showing 20 of 239 recruiting Cancer trials in Nebraska

Pan Tumor Rollover Study
PHASE2 Huntsville, Alabama +4 sites NCT03899155
This trial is looking for patients with cancer who have had a good response to previous treatments. Participants will continue receiving nivolumab alone or in combination with other cancer therapies to study long-term safety.
Recruiting
Integrated Cancer Repository for Cancer Research
N/A Greenwood Village, Colorado +4 sites NCT02012699
This trial is looking for adults who have a history of cancer, are at risk for developing cancer, or are healthy individuals. Participants will provide consent and may help advance cancer research by sharing data and samples.
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
PHASE3 Tucson, Arizona +4 sites NCT06136650
This trial is looking for men with metastatic castration-resistant prostate cancer who have been treated with one hormonal therapy before. Participants will receive either opevesostat with corticosteroids or other alternative treatments to see which is more effective.
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
PHASE3 Birmingham, Alabama +4 sites NCT06901531
This trial is looking for adults with advanced stomach or gastroesophageal junction cancer. Participants will receive a combination of zolbetuximab, pembrolizumab, and chemotherapy, or a placebo with pembrolizumab and chemotherapy to see how well it works.
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
PHASE3 Mobile, Alabama +4 sites NCT07472517
This trial is looking for adults with advanced small cell lung cancer. Participants will receive either a study medicine called obrixtamig along with standard treatment or just the standard treatment alone. The goal is to see if the study medicine helps improve survival.
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
PHASE3 Birmingham, Alabama +4 sites NCT04928846
This trial is looking for adults with a type of lung cancer who have already had treatment. Participants will receive either telisotuzumab vedotin or docetaxel through an IV every couple of weeks to see how well they work and how safe they are.
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT05827081
This trial is looking for adults with early breast cancer that is hormone receptor positive and HER2 negative. If you join, you will receive ribociclib along with standard hormone therapy to see how effective this combination is.
Recruiting
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
PHASE3 Sacramento, California +4 sites NCT07513376
This trial is looking for people with high-risk non-small cell lung cancer that has been surgically removed. Participants will receive either one or two investigational treatments to help prevent the cancer from coming back after surgery.
Recruiting
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
PHASE3 Dothan, Alabama +4 sites NCT07611110
This trial is looking for men with advanced prostate cancer that hasn't responded to standard treatments. Participants will receive AZD2265 to see if it works better than standard care.
Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
PHASE3 Anchorage, Alaska +4 sites NCT06764875
This trial is looking for individuals with advanced stomach cancer that tests positive for HER2. Participants will receive a combination of rilvegostomig, chemotherapy, and other treatments to see how well it works.
Recruiting
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
PHASE3 Birmingham, Alabama +4 sites NCT07492641
This trial is looking for people with advanced breast cancer who have not been treated for it before. Participants will receive either BGB-43395 with letrozole or a different treatment option with letrozole.
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
PHASE3 Huntsville, Alabama +4 sites NCT07562152
This trial is looking for adults with advanced pancreatic cancer. Participants will receive a combination treatment to see how effective and safe it is compared to standard treatment.
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
PHASE2 Birmingham, Alabama +4 sites NCT06712316
This trial is looking for people with advanced non-small cell lung cancer who have not received any treatment yet. Participants will receive a new treatment combined with chemotherapy and will be monitored for their health outcomes.
Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
PHASE3 Homewood, Alabama +4 sites NCT06855277
This trial is looking for adult men with a specific type of prostate cancer called PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). Participants will receive a treatment called AAA817 along with other medications to see if it improves their condition.
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
PHASE3 Phoenix, Arizona +4 sites NCT06925737
This trial is looking for men with advanced prostate cancer that has spread. By participating, I may receive a treatment called ifinatamab deruxtecan and help researchers learn if it works better than standard chemotherapy.
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
PHASE3 Tucson, Arizona +4 sites NCT06712355
This trial is looking for patients with untreated extensive-stage small-cell lung cancer. Participants will receive either BNT327 combined with chemotherapy or a different combination of treatments to see which works better.
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
PHASE2 Goodyear, Arizona +4 sites NCT04613596
This trial is looking for patients with advanced non-small cell lung cancer who have a specific mutation. Participants will receive treatments to see how well they work.
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
PHASE3 Birmingham, Alabama +4 sites NCT05633654
This trial is looking for adults with triple negative breast cancer that remains after surgery and treatment. Participants will receive an experimental treatment combining two medications after recovery from surgery.
Recruiting

Where the Cancer studies are in Nebraska

  • University of Nebraska Medical Center, Omaha68 trials
  • Nebraska Cancer Specialists, Omaha34 trials
  • CHI Health Good Samaritan, Kearney29 trials
  • Nebraska Medicine-Village Pointe, Omaha28 trials
  • Alegent Health Bergan Mercy Medical Center, Omaha25 trials
  • Nebraska Medicine-Bellevue, Bellevue25 trials

Counts are recruiting studies listing at least one site in Nebraska, from ClinicalTrials.gov, refreshed every two days.

Cancer clinical trials in Nebraska: common questions

How many Cancer clinical trials are recruiting in Nebraska?
TrialFinder currently lists 239 recruiting Cancer clinical trials with study sites in Nebraska. Results are updated regularly from ClinicalTrials.gov, the official U.S. registry of clinical studies.
Where are Cancer clinical trials located in Nebraska?
Study sites for the Cancer trials listed on this page include Lincoln. Each trial page lists every participating site with contact details, so you can find the location closest to you.
Do I need insurance to join a Cancer clinical trial in Nebraska?
No. Study-related care is covered by the trial sponsor at no cost to participants, including the study treatment, required lab tests and study visits. Many Cancer trials in Nebraska also compensate participants for time and travel. Health insurance is not required to search or enroll.
How do I qualify for a Cancer clinical trial in Nebraska?
Each study sets its own criteria based on age, Cancer diagnosis details, prior treatments, current medications and general health. The fastest way to find out is to contact a research site directly — most will pre-screen you by phone in 10 to 15 minutes at no charge. You can also create a free TrialFinder profile to be matched automatically.
Will I get a placebo instead of cancer treatment?
Almost never. Cancer trials compare a new treatment with the current standard treatment, or add the study drug to standard treatment. When a placebo is used it is on top of standard care, and the consent form states this before you decide.
Can I join a cancer trial if my cancer has spread?
Yes. Many recruiting cancer trials are written for advanced or metastatic disease, including people whose earlier treatments have stopped working. The listing states the stage and prior treatments it accepts.
Do I have to stop my current cancer treatment to join a trial?
It depends on the trial. Some enroll people whose current treatment has stopped working, some add the study drug to the treatment you are on, and some are for people who have not started treatment yet. Ask the study team before changing anything.
Are Clinical Trials Safe? What Patients Should Know
How clinical trial safety works — phases, IRB oversight, informed consent, and your right to withdraw — plus the real risks and questions to ask.
How to Know If You Qualify for a Clinical Trial
Every trial has eligibility criteria based on diagnosis, age, and medical history. Here's how to tell if you qualify — and what to do if you're not sure.
Clinical Trials Without Insurance: What You Need to Know
Clinical trials cover the cost of study-related care, making them one of the few ways to access treatment without health insurance. Here's what's covered.
All guides →

Check Your Eligibility

Create a free profile and our AI will match you to Cancer trials near you in Nebraska.

Get Matched — Free
No insurance required

Breast cancer trials test new chemotherapy regimens, immunotherapy combinations, targeted therapies, and early-detection methods across all stages of breast cancer.

All Cancer trials →